SandboxAQ launches Virtual Screening Solution for GPCR Drug Discovery, accelerated by NVIDIA BioNeMo.

{
  "signal_id": "41d76f24-1e73-4281-80e2-1016c3d3b495",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-06-23T14:00:00+00:00",
  "company": {
    "name": "SandboxAQ",
    "domain": "sandboxaq.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/sandboxaq-launches-virtual-screening-solution-for-gpcr-drug-discovery-accelerated-by-nvidia-bionemo-302807357.html",
    "title": "SandboxAQ launches Virtual Screening Solution for GPCR Drug Discovery, accelerated by NVIDIA BioNeMo.",
    "excerpt": "SandboxAQ launches Virtual Screening Solution for GPCR Drug Discovery, accelerated by NVIDIA BioNeMo.\n\nJun 23, 2026, 09:00 ET\n\nPALO ALTO, Calif., June 23, 2026 /PRNewswire/ - SandboxAQ today announced a new virtual screening solution that helps drug developers identify promising candidates faster and at lower cost for G protein-coupled receptors (GPCRs), one of the most valuable yet hardest-to-drug families of targets. Accelerated by NVIDIA BioNeMo Agent Toolkit, the GPCR Virtual Screening Solution predicts both whether a molecule binds a receptor and whether it is likely to activate the receptor or block its activation.\n\nGPCRs are the targets of roughly a third of all approved drugs, including the GLP-1 medicines for diabetes and obesity, yet they remain notoriously difficult to drug. Because these receptors can shift between \"on\" and \"off\" states, a successful medicine must not only bind, but bind in a way that stabilizes the right state and produces the desired biological effect.\n\nThat is where the GPCR Virtual Screening Solution can help. It helps researchers predict what a GPCR ligand, whether a small molecule or peptide, will do - not just whether it binds. By forecasting how tightly a molecule binds to different receptor conformations and modeling its preference for the receptor's active versus inactive state, the Virtual Screening Solution infers functional activity...",
    "product": "Virtual Screening Solution for GPCR Drug Discovery",
    "summary": "SandboxAQ launched Virtual Screening Solution for GPCR Drug Discovery on Jun 23rd '26.",
    "location": "Palo Alto, California, United States, Northern America, Americas",
    "planning": false,
    "image_url": "https://mma.prnewswire.com/media/2372842/SandboxAQ_Accent_Color_Black_TM_Logo.jpg?p=facebook",
    "confidence": 0.9837,
    "product_data": {
      "full_text": "Virtual Screening Solution for GPCR Drug Discovery",
      "fuzzy_match": true
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-06-23T14:00:00Z",
    "location_data": [
      {
        "city": "Palo Alto",
        "state": "California",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-06-23",
    "job_title_tags": [
      "general_technology"
    ],
    "article_sentence": "SandboxAQ launches Virtual Screening Solution for GPCR Drug Discovery, accelerated by NVIDIA BioNeMo."
  }
}

curl https://signals.autobound.ai/v1/signals/41d76f24-1e73-4281-80e2-1016c3d3b495 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"sandboxaq.com","limit":20}'